Selvita Appoints Chief Medical Officer Steffen Heeger, M.D., MSc., to Executive Management Board

Krakow, Poland – 15 March 2019 – Selvita (WSE:SLV), a clinical stage drug discovery and development company engaged in the research and development of novel cancer therapies, today announced the appointment of Steffen Heeger, M.D., MSc., to the Executive Management Board of the Company as of April 1, 2019. Dr. Heeger was appointed Chief Medical Officer of Selvita in February 2018.

 

“As a member of the Executive Board, Dr. Heeger will contribute to crafting corporate strategy at the highest level,” commented Pawel Przewiezlikowski, Chief Executive Officer of Selvita. “His experience will help us advance our clinical programs as efficiently as possible and prioritize the many opportunities for pipeline expansion provided by our discovery engine.”

 

Prior to joining Selvita, Dr. Heeger led clinical development and clinical operations for hematology and oncology therapeutics at Morphosys AG. Dr. Heeger’s experience includes a nine-year tenure at Merck Serono, where he was Head of Medical Affairs and led the Global Clinical Development Team for Erbitux. Dr. Heeger studied Medicine in, Heidelberg, Mannheim and Freiburg and continued his medical training at the Department of Hematology and Oncology of the Heidelberg University Hospital. Simultaneously with his training in medicine, he held a research position at the German Cancer Research Center (DKFZ) in Heidelberg. He received a M.D. in Medicine from the University of Heidelberg.

 


About Selvita

Selvita is developing novel small molecule therapies that address emerging targets in oncology with industry-leading research expertise supported by a research services division. Pipeline candidates apply diverse mechanisms directed at kinases, synthetic lethality pathways, immuno-oncology pathways and other cancer-related targets. SEL24 is a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group in clinical development for the treatment of acute myeloid leukemia. SEL120 is a CDK8 kinase inhibitor with potential for development in indications including hematological malignancies and solid tumors. Selvita is headquartered in Krakow with offices in the U.S. and U.K.

 

 

Contact:

Julia Balanova (investors)
+1 646 378 2936
jbalanova@troutgroup.com

Rich Allan (media)
+1 646 378 2958
rallan@troutgroup.com

Malgorzata Syjud (corporate)
+48 660 797 362
malgorzata.syjud@selvita.com

 

Click to share!: